Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases, JA Clinical Reports, November 29, 2025

This is a small study but it addresses a very important but often overlooked issue, that of injection site pain for pulmonary arterial hypertension patients being treated with sub-cutaneous treprostinil, which can significantly affect quality of life. The researchers found that topical 10% lidocaine gel provided rapid and effective relief of injection site pain, facilitating […]

Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases, JA Clinical Reports, November 29, 2025 Read Post »

Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension, Pulmonary Circulation, November 20, 2025

Pulmonary arterial hypertension (PAH) is a progressive, life-threatening disease where early detection is strongly encouraged to prevent irreversible vascular and cardiac damage. However, a fundamental paradox exists: while clinicians are urged to diagnose pulmonary arterial hypertension early, treatment is restricted to symptomatic patients (New York Heart Association (NYHA) functional class II or higher), leaving asymptomatic

Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension, Pulmonary Circulation, November 20, 2025 Read Post »

Publication of a new European Medicines Agency (EMA) booklet on medicine safety monitoring

The European Medicines Agency (EMA) has published a new booklet on the safety monitoring of medicines in the European Union. It provides an overview of how the European Medicines Agency and European Union Member States work to ensure that medicines used across Europe remain safe throughout their lifecycle.  The booklet is published on a new

Publication of a new European Medicines Agency (EMA) booklet on medicine safety monitoring Read Post »

Comparing Pulmonary Arterial Hypertension Care in Urban and Rural Settings: Treatment Patterns and Risk Trajectories, Pulmonary Circulation, November 11, 2025

Access to specialized care may differ between urban and rural patients, potentially influencing outcomes. A study conducted at the at the University of Utah Pulmonary Hypertension Center compared 263 pulmonary arterial hypertension patients from urban versus rural areas treated in the period 2020-2024. Similar at baseline: Important differences emerged: Conclusion: Despite similar care delivery and

Comparing Pulmonary Arterial Hypertension Care in Urban and Rural Settings: Treatment Patterns and Risk Trajectories, Pulmonary Circulation, November 11, 2025 Read Post »

New pulmonary arterial hypertension therapy CM5480 delivers encouraging results in rat model, Pulmonary Hypertension News, November 14, 2025

CM5480 is an experimental therapy being developed by Calcimedica, a US clinical-stage biopharmaceutical company. The findings of a new study titled “Combination of Orai1 inhibitor CM5480 with specific therapy mitigates pulmonary hypertension and its cardiac dysfunction” reveals that CM5480 was helpful in rat models when used on its own and provided additional benefits when combined

New pulmonary arterial hypertension therapy CM5480 delivers encouraging results in rat model, Pulmonary Hypertension News, November 14, 2025 Read Post »

Integrating Sotatercept Into Pulmonary Arterial Hypertension (PAH) Care: Vallerie McLaughlin, MD, American Heart Association, November 9, 2025

Vallerie McLaughlin, MD, the Kim A. Eagle M.D. Endowed Professor of Cardiovascular Medicine and Professor of Internal Medicine at the University of Michigan Medical School, presented the results of a pooled analysis of the PULSAR, STELLAR, and ZENITH trials of sotatercept in pulmonary arterial hypertension at the 2025 American Heart Association Scientific Sessions, held in

Integrating Sotatercept Into Pulmonary Arterial Hypertension (PAH) Care: Vallerie McLaughlin, MD, American Heart Association, November 9, 2025 Read Post »

Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial Hypertension (PAH) to the U.S. Food and Drug Administration (FDA), November 10, 2025

Cereno Scientific has submitted the clinical trial protocol for the planned global Phase IIb trial of its lead drug candidate CS1 to the U.S. Food and Drug Administration (FDA). CS1 is an oral histone deacetylase inhibitor (HDACi) intended as a disease-modifying therapy for pulmonary arterial hypertension (PAH), working through epigenetic modulation to target underlying mechanisms

Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial Hypertension (PAH) to the U.S. Food and Drug Administration (FDA), November 10, 2025 Read Post »

First clinical site now open for large trial testing seralutinib for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), Pulmonary Hypertension News, November 7, 2025

The first clinical site is now active for a global Phase 3 study that will evaluate Gossamer Bio’s therapy candidate seralutinib for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study, titled SERANATA, aims to enroll around 480 patients aged 18 to 80, randomised to receive either 90 mg or 120 mg

First clinical site now open for large trial testing seralutinib for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), Pulmonary Hypertension News, November 7, 2025 Read Post »

Preferences for pulmonary arterial hypertension (PAH) medications: insights from interviews with patients and doctors, Future Cardiology, November 4, 2025

A study titled “Single‑Tablet Combination Therapy of Macitentan/Tadalafil for Patients with Pulmonary Arterial Hypertension: Qualitative Interview Study” interviewed 26 pulmonary arterial hypertension patients and 18 doctors from the A DUE clinical trial, who tested the single-pill combination therapy (macitentan+tadalafil) versus taking multiple pills daily. Both patients and doctors agreed that taking one pill daily instead

Preferences for pulmonary arterial hypertension (PAH) medications: insights from interviews with patients and doctors, Future Cardiology, November 4, 2025 Read Post »

Economic and Social Burden of Pulmonary Arterial Hypertension in Italy: A Cost-of-Illness Study, Drugs Real World Outcomes, October 17, 2025

A paper titled “Economic and Social Burden of Pulmonary Arterial Hypertension in Italy: A Cost-of-Illness Study” was recently pubclished in Drugs Real World Outcomes journal. The aim of the authors was to estimate the economic and social burden of pulmonary arterial hypertension (PAH) in Italy, including direct healthcare costs, direct non-healthcare costs, and indirect costs

Economic and Social Burden of Pulmonary Arterial Hypertension in Italy: A Cost-of-Illness Study, Drugs Real World Outcomes, October 17, 2025 Read Post »

Comparative efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension: a systematic review and network meta-analysis, Frontiers in Medicine, October 2025

A network meta-analysis conducted by researchers at the Cleveland Clinic Abu Dhabi, published in the October 2025 edition of Frontiers in Medicine, compared the efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension (PAH) by synthesizing data from 32 studies, comprising 24 randomised controlled trials, three open-label trials,and five cohort studies, with a cumulative

Comparative efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension: a systematic review and network meta-analysis, Frontiers in Medicine, October 2025 Read Post »

How Medicine Missed Viagra’s True Potential, MedPage Today, October 15, 2025

A recent article by Bharat Desai, an American physician specializing in internal medicine and pulmonary disease, argues that sildenafil could have revolutionized cardiovascular prevention, but was relegated to being an erectile dysfunction drug due to the at-the-time medical environment’s obsession with cholesterol. The Forgotten Origins Sildenafil was originally developed in the early 1990s as a

How Medicine Missed Viagra’s True Potential, MedPage Today, October 15, 2025 Read Post »

Pulmonary vascular diseases – State of the art session, European Respiratory Society Annual Congress 2025, Septermber 28, 2025

On Monday, 28 September 2025, a State of the Art Session was held at the European Respiratory Society (ERS) Annual Congress 2025 titled: “Pulmonary Hypertension associated with lung diseases: the most burning questions.” The session was chaired by Prof. Dr. Olivier Sitbon, Prof. Dr. David Montani, and Dr. Nesrin Ocal. Leading experts shared the latest

Pulmonary vascular diseases – State of the art session, European Respiratory Society Annual Congress 2025, Septermber 28, 2025 Read Post »

Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis, New England Journal of Medicine, September 30, 2025

The phase 3 HYPERION trial on sotatercept enrolled 320 adults with newly diagnosed pulmonary arterial hypertension (within 1 year of diagnosis) at intermediate or high risk who were already on double or triple background therapy. Patients were randomized to receive add-on subcutaneous sotatercept or placebo every 21 days. The trial stopped early due to compelling

Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis, New England Journal of Medicine, September 30, 2025 Read Post »

Anticoagulation and Survival in Pulmonary Arterial Hypertension: Findings from Large French Registry (1.500+ patients), Journal of the American College of Cardiology, September 30, 2025

Despite historical use, the role of anticoagulant therapy in the management of pulmonary arterial hypertension (PAH) remains uncertain, as existing epidemiologic studies have produced conflicting results. The goal of a study whose findings were published in the Journal of the American College of Cardiology on September 30, 2025, was to examine the association between anticoagulant

Anticoagulation and Survival in Pulmonary Arterial Hypertension: Findings from Large French Registry (1.500+ patients), Journal of the American College of Cardiology, September 30, 2025 Read Post »

Gossamer Bio and Respira Therapeutics have entered into an option agreement to develop Respira’s pulmonary hypertension treatment candidate RT234, Pulmonary Hypertension News, September 26, 2024

Gossamer Bio has an option to acquire Respira Therapeutics and its inhaled pulmonary arterial hypertension treatment RT234. Gossamer plans to develop RT234 for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), the same two indications for which it is already developing its own inhaled treatment candidate, seralutinib. RT234 is an inhaled formulation

Gossamer Bio and Respira Therapeutics have entered into an option agreement to develop Respira’s pulmonary hypertension treatment candidate RT234, Pulmonary Hypertension News, September 26, 2024 Read Post »

New study reveals how BMP-9 regulates lung vessels, opening doors for future pulmonary arterial hypertension therapies, new findings from a Franco-German study, Proceedings of the National Academy of Sciences of the USA (PNAS), July 2025

  Pulmonary arterial hypertension (PAH) happens when the blood vessels in the lungs become too narrow and stiff. This raises pressure in the lungs and puts strain on the heart. In a collaborative study, scientists from Inserm and Université Paris-Saclay in France, together with researchers from the Institute for Lung Health (ILH) in Germany, discovered

New study reveals how BMP-9 regulates lung vessels, opening doors for future pulmonary arterial hypertension therapies, new findings from a Franco-German study, Proceedings of the National Academy of Sciences of the USA (PNAS), July 2025 Read Post »

Data on investigational treprostinil transdermal patch system to be presented at professional symposium organised by the US Pulmonary Hypertension Association, September 18-20, 2025

Corsair Pharma will present preclinical data on their TRX-248 transdermal patch at the Pulmonary Hypertension Professional Network Symposium (PHPPN), Sept 18-20, 2025. The once-daily patch delivers treprostinil for pulmonary arterial hypertension treatment. These data provide additional support for the clinical program which is currently in a first-in-human Phase 1 study. The transdermal patch has the

Data on investigational treprostinil transdermal patch system to be presented at professional symposium organised by the US Pulmonary Hypertension Association, September 18-20, 2025 Read Post »

Understanding Risk Assessment in Pulmonary Arterial Hypertension, International Society for Heart and Lung Transplant ISHLT Consensus Statement, The Journal of Heart and Lung Transplantation – September 05, 2025

What is pulmonary arterial hypertension and why does risk assessment matter? Pulmonary arterial hypertension is a rare, serious disease where the blood vessels in thelungs become too narrow. This makes the right side of the heart work harder, which overtime can lead to heart failure. Because it can progress quickly, doctors use risk assessment (sometimes

Understanding Risk Assessment in Pulmonary Arterial Hypertension, International Society for Heart and Lung Transplant ISHLT Consensus Statement, The Journal of Heart and Lung Transplantation – September 05, 2025 Read Post »

Cereno Scientific Granted FDA Fast Track Designation for CS1 Investigational Drug for Pulmonary Arterial Hypertension (PAH)

Cereno Scientific announced on August 26, 2025 that the US Food and Drug Administration (FDA) has granted Fast Track designation to CS1, its lead drug candidate for treating pulmonary arterial hypertension (PAH). This designation accelerates development and regulatory review for treatments addressing serious conditions with high unmet medical need. In a Phase IIa trial, it

Cereno Scientific Granted FDA Fast Track Designation for CS1 Investigational Drug for Pulmonary Arterial Hypertension (PAH) Read Post »

TRANSLATE »
Scroll to Top